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February 2016 Letters to the Editor e27is addressed on page 71 of the WHO blue book, where it
also stated that NE stains are not recommended
for routine use in tumors lacking NE morphologic
features.1 The WHO committee did not consider this
problem important enough to warrant a formal title in
the classiﬁcation; however, the recommendation that
testing for NE immunohistochemical markers in the
absence of NE morphologic features not be performed
in either the nonresection or resection specimen
settings is important and should not be overlooked.
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1243–1260.Genetic Basis of
Mesothelioma—More Than
Asbestos ExposureTo the Editor:
A combination of pathogenic organisms, environmental
carcinogen, and genetic predisposition can contribute
to carcinogenesis. No causative viruses for mesotheli-
oma have been identiﬁed to date, and even though
mesothelioma has been attributed largely to asbestos
exposure, the genetic basis underlying the disease has
lately received attention. Such interest is warranted
because asbestos alone cannot explain the varying
incidence of mesothelioma among patients with com-
parable exposure, and most diseases have a multifac-
torial etiology.
Thus, researchers were excited to ﬁnd that mutations
in a tumor suppressor gene, breast cancer 1–associated
protein 1 (BAP1), were found in families with a high
incidence of mesothelioma, as well as in sporadic cases.1Interestingly, both germline and somatic mutations were
found, which indicated a possible inheritance of the
disease, as well as establishment of BAP1 as a target of
mutations. All family members had nonoccupational,
residential asbestos exposure; thus, the relationship
between BAP1 mutations and asbestos might be
additive, synergistic, or both.
Recently, Nasu et al.2 found somatic mutations of
BAP1 in more than 60% of 22 frozen mesothelioma
biopsies, and they duplicated their ﬁnding in another 70
biopsy samples. There was no signiﬁcant correlation
between frequency of BAP1 mutations and asbestos
exposure among patients, which implied that the
pathogenesis of mesothelioma may be multifactorial and
possibly polygenic.
For instance, germline and somatic mutations in
transcriptional regulators such as mammalian switch/
sucrose nonfermentable (mSWI/SNF) chromatin
remodeling complex were noted in mesothelioma.3
Such mutations may cause low acetylation of histone
and affect transcription, thereby contributing to the
development of mesothelioma. Even though these
results were obtained from eight mesothelioma cell
lines from patients who all had a history of asbestos
exposure, they supported interplay between genetic
predisposition and asbestos as a contributor to
development of disease.
Furthermore, somatic mutations were reported in
tumor suppressor genes, including neuroﬁbroma-
tosis type 2 (NF2), large tumor suppressor 2 (LATS2),
e28 Letters to the Editor Journal of Thoracic Oncology Vol. 11 No. 2cyclin-dependent kinase inhibitor 2A (CDKN2A), and
Cullin 1(CUL1), in mesothelioma cell lines and tissues.4,5
Many of these mutations affect pathways, including
the Hippo, cell cycle, mitogen-activated protein kinase
(MAPK), and wingless-type (Wnt) pathways. In addition
to somatic mutations, several fusion transcripts, such
as LATS1–presenilin 1 (PSEN1), were identiﬁed. A
downstream effect of such fusion was the inability to
suppress mesothelioma cell growth in vitro. The cell
lines and tissues originated from patients, many of
whom reported asbestos exposure (and some who did
not might have had residential exposure).
Reports in the literature thus far point toward
asbestos exposure as the predominant cause of meso-
thelioma, with susceptibility increased by genetic pre-
disposition. Whether a genetic mutation by itself is
sufﬁcient to cause mesothelioma has not been shown,
yet. With identiﬁcation of new candidate genes and
clariﬁcation of their function in the context of mesothe-
lioma, our understanding of its carcinogenesis will in-
crease even further.Address for correspondence: Silvio Roncella, PhD, Division of
Histopathology and Cytopathology, P.O. San Bartolomeo, ASL5 Via
Cisa, Loc. Santa Caterina, Sarzana (SP), Italy, 19038. E-mail: Silvio.
roncella@asl5.liguria.it
ª 2015 International Association for the Study of Lung Cancer.
Published by Elsevier Inc. All rights reserved.
ISSN: 1556-0864
http://dx.doi.org/10.1016/j.jtho.2015.10.019Daniel Lee, MD, PhD
Center for Cancer Research
National Cancer Institute, National Institutes of Health
Bethesda, Maryland
References
1. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations
predispose to malignant mesothelioma. Nat Genet.
2011;43:1022–1025.
2. Nasu M, Emi M, Pastorino S, et al. High incidence of so-
matic BAP1 alterations in sporadic malignant mesotheli-
oma. J Thorac Oncol. 2015;10:565–576.
3. Yoshikawa Y, Sato A, Tsujimura T, et al. Biallelic germline
and somatic mutations in malignant mesothelioma: mul-
tiple mutations in transcription regulators including
mSWI/SNF genes. Int J Cancer. 2015;136:560–571.
4. Miyanaga A, Masuda M, Tsuta K, et al. Hippo pathway gene
mutations in malignant mesothelioma: revealed by RNA and
targeted exon sequencing. J Thorac Oncol. 2015;10:844–851.
5. Guo G, Chmielecki J, Goparaju C, et al. Whole-exome
sequencing reveals frequent genetic alterations in BAP1,
NF2, CDKN2A, and CUL1 in malignant pleural mesotheli-
oma. Cancer Res. 2015;75:264–269.MET Gene Status in
Malignant Mesothelioma
Using Fluorescent In Situ
HybridizationTo the Editor:
In our October 2015 letter in the Journal1 we reported
a patient with malignant mesothelioma (MM) with
ampliﬁcation of the MET gene associated with MET
receptor expression. This ﬁnding suggests that the
inhibition of MET might be used as a targeted therapy
also in selected patients with MM.2
We now report a MET copy number analysis in pa-
tients with MM scored by the Union for International
Cancer Control criteria proposed for stratiﬁcation of
non–small cell lung cancer according to the EGFR ﬂuo-
rescence in situ hybridization (FISH) assay and also
used by Go et al.3 for the scoring of MET. MET status was
classiﬁed as FISH-positive and -negative according to the
frequency of MM cells with speciﬁc copy numbers of the
MET gene and chromosome 7 centromere (CEP7).3This study was approved by the Liguria Region Ethics
Committee, and written informed consent was obtained
from all patients.
We analyzed 60 patients with MM (male, 66.7%;
median age, 60.0 years [range, 5–85 years]), including
patients with epithelioid (n ¼ 36), sarcomatoid (n ¼ 12),
biphasic (n ¼ 8), desmoplastic (n ¼ 2), and papillary
(n ¼ 2) subtypes. Thirty cases of MM were from a tissue
microarray (MS801; US Biomax Inc, Rockville, MD), 12
cases of formalin-ﬁxed parafﬁn-embedded tissues were
from the Unit of Pathology, IRCCS A.O.U. San Martino–
IST (Genova, Italy), and 18 cases were from the Division
of Histopathology (ASL5, La Spezia, Italy).
We found 5 FISH-positive cases (8.3%), of which one
epithelioid MM had MET ampliﬁcation (about 8 MET
signals on >70% of cells; MET/CEP7 ratio ¼ 4.0; Fig. 1A)
and four epithelioid MMs showed high polysomy of MET
(range of 4–10 spots of MET in about 60%–80% of MM
cells; a representative case is shown in Fig. 1D). All the
other 55 FISH-negative cases (91.7%) were disomic
for MET (a representative case is shown in Fig. 1G).
As in the previously reported case, IHC analysis
showed that ampliﬁcation was associated with moderate
expression of MET protein in cytoplasm and membrane
of MM cells (Fig. 1B). In contrast, high gene polysomy
resulted in low staining of MET protein (Fig. 1E).
In our study, we found that MET ampliﬁcation is a
rare event in patients with MM (1.7% of total cases) in
contrast to MET polysomy, which occurs more
frequently (6.7% of total cases). The biological impact
of MET polysomy on cancer cells has not been well
established. However, highly polysomic status in MM
